|E.L. Wynder, MD, American Health Foundation (AHF), New York City, presented the American Cancer Society Distinguished Lecture. The talk reviewed data from nutrition studies as early as 1942. Since dietary fat correlates highly with cancer of the breast and prostate, Wynder started two two important intervention studies on both diseases.|
In 1942, Tannebaum showed increased breast cancer in animals
fed a high fat diet. Later research identified linoleic acid
above two percent as facilitating this cancer's development.
Recent analysis of ethnic differences in percent consumed
dietary fat yielded a significant correlation with breast
cancer deaths (J Clin Epidem 1994;47:217-22).
Wynder referred to the complementary role of diet to tomoxifen treatment of breast cancer (Lancet,1992;339:1-15). This study prompted recent initiation of the AHF-coordinated, multicenter study on 2500 stage I and II postmenopausal breast cancer patients. The protocal calls for tamoxifen or other chemotherapy with a low fat diet (15% of total calories) or a high fat diet (30% of total calories).
Dietary fat seems to make prostate cancer more invasive
according to a 1973 study comparing native Japanese men with
first generation Hawaiian Japanese. Clark et al showed increased
dietary selenium led to a 70% decrease in prostate cancer and
a 50% decrease in colon cancer (JAMA 1996;276:1957-1963).
A few months ago, Wynder started the Prostate Intervention Nutrition Study (PINS). Post-prostatectomy patients showing an elevation in prostate-specific antigen (PSA) will enter one of four groups. Group 1 continues without dietary supplements or restrictions. Group 2 switches to a low fat diet (15%). Group 3 adds a daily supplement of 200 mcg selenium along with 40 g of soy proteins and 800 IU of vitamin E. Group 4 consumes a low fat diet and takes the Group 3 supplements. Prostate-specific antigen (PSA) will serve as the efficacy marker for the study.
Wynder, as expected, concluded the lecture with some advice:
For professional correspondence, please contact Dr. Wynder at: fax (212) 687-2339
Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on May 17-20, 1997
CONRAD NOTES, © 1997 All Rights Reserved
Eugene A. Conrad, PhD, MPH / ISSN 1078 / June 1997